John Mark O'Mahony - Mar 28, 2025 Form 4 Insider Report for LEAP THERAPEUTICS, INC. (LPTX)

Role: Chief Manufacturing Officer
Signature: /s/ Douglas E. Onsi, as attorney-in-fact for John Mark O'Mahony
Stock symbol: LPTX
Transactions as of: Mar 28, 2025
Transactions value $: $0
Form type: 4
Date filed: 4/1/2025, 09:52 PM
Previous filing: Oct 4, 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LPTX	Common Stock	Options Exercise		+22.5K	+450%		27.5K	Mar 28, 2025	Direct	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LPTX	Restricted Stock Units	Options Exercise	$0	-22.5K	-100%	$0.00	0	Mar 28, 2025	Common Stock	22.5K		Direct	F1, F3, F4, F5, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 such that the Company issued to the reporting person on such settlement date all of the 22,500 shares of the Company's common stock underlying the January 22 RSUs.
F2	The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023.
F3	Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock.
F4	The January 2022 RSUs became fully vested on January 31, 2025 but settlement thereof was deferred by the Compensation Committee of the Board of Directors of the Company until March 28, 2025 pursuant to, and in accordance with, the terms of the January 2022 RSUs, which terms provide that the Compensation Committee would have the authority to defer the settlement of the January 2022 RSUs to a date later than the vesting date of the January 2022 RSUs in the event that on such vesting date the reporting person were to be subject to, among other things, any limitation or restriction under the Company's insider trading policy that would not permit the reporting person to sell on such vesting date all of the shares of the Company's Common Stock underlying the January 2022 RSUs if the January 2022 RSUs were to be settled on such vesting date.
F5	The Compensation Committee of the Board of Directors took action to defer settlement of the January 2022 RSUs so that such settlement would not occur on January 31, 2025, the vesting date thereof. The January 2022 RSUs were settled on March 28, 2025 as further described on note (2) above.
F6	The terms of the January 2022 RSUs provide that the January 2022 RSUs would automatically terminate and be forfeited upon termination of the reporting person's employment or other service relationship with the Company if such termination of employment or service relationship were to occur at any time prior to January 31, 2022, the vesting date of the January 2022 RSUs.